TAE Life Sciences Raises $30M in Initial Series B Funding

TAE Life Sciences

Tae Life Sciences, a Foothill Ranch, Calif.-based biological-targeting radiation therapy company developing boron neutron capture therapy solutions, raised $30M in funding.

The initial phase of the B-round funds come from a consortium of investors including Artis Ventures, who led the company’s initial funding in 2018.

Led by Kendall Morrison, Chief Scientific Officer, and Bruce Bauer, Chief Executive Officer, TAE Life Sciences aims to advance Boron Neutron Capture Therapy (BNCT), a particle therapy designed to selectively destroy cancer cells without damaging neighboring healthy cells.

The company intends to use the funds to continue to move beyond the current boron-10 drug, BPA, and speed development of novel proprietary boron-10 target drugs at the same time that it hones its neutron beam accelerator technology for BNCT.

TAE has established a state-of-the-art drug development facility in Santa Monica, Calif., that includes dedicated labs for cell biology and antibody production, medicinal chemistry, and molecular biology.



Join the discussion